This is a summary of the European public assessment report (EPAR) for Clopidogrel TAD. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Clopidogrel TAD.
For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.
Clopidogrel TAD : EPAR - Summary for the public (PDF/84.95 KB)
First published: 15/10/2009
Last updated: 13/09/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Tad Pharma GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
20/09/2019 Clopidogrel TAD - EMEA/H/C/001136 - IB/0033
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.